AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Viridian Therapeutics, Inc.
Video analysis: VRDN
All videosNo video analysis for this stock yet. Request one from our team.
News: VRDN
Viridian Intersects Over 50 Metres of Mineralization from Surface at Kraken Main
OTTAWA, Ontario, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (OTCQB: VIRMF) reports initial assay results from its 2026 drill program at the Kraken Main Zone in Labrador.
27,472 Shares in Viridian Therapeutics, Inc. $VRDN Acquired by Jupiter Topco LLC
Jupiter Topco LLC acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ: VRDN) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 27,472 shares of the company's stock, valued at approximately $505,000. A number of other hedge
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that senior management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 12:45pm ET. A live webcast of the fireside chat can be accessed under “Events and Presentations” on the Invest.
Algert Global LLC Sells 81,762 Shares of Viridian Therapeutics, Inc. $VRDN
Algert Global LLC lowered its position in Viridian Therapeutics, Inc. (NASDAQ: VRDN) by 14.5% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 482,237 shares of the company's stock after selling 81,762 shares during the period. Algert Global LLC
Deutsche Bank AG Invests $8.87 Million in Viridian Therapeutics, Inc. $VRDN
Deutsche Bank AG bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ: VRDN) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 482,875 shares of the company's stock, valued at approximately $8,870,000. Deutsche Bank AG owned about 0.47% of Viridian Therapeutics at
Viridian Reports Continuation of Massive Sulphides at Kraken Main; First Assays Pending
OTTAWA, Ontario, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Assays are now pending from the first diamond drill holes completed as part of Viridian Metals Inc.'s (CSE: VRDN) (OTCQB: VIRMF) 2026 drill program at the Kraken project in Labrador. The initial assay submission includes the extension of hole VKS25-024, which previously returned 24.05 metres grading 0.77% CuEq¹ (0.21% Cu, 0.30% Ni, 0.04% Co) from 1 metre before terminating in mineralization (see Viridian news release dated February 26, 2025).
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30, 2026. “We are very encouraged by the early indications from our recent launch of Lumvoa as we start a new chapter for Viridian as a commercial-stage company,” said Steve.
